Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor
Open Access
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (8) , 1151-1155
- https://doi.org/10.1023/a:1011628900089
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell CancerJournal of Clinical Oncology, 2001
- Randomized Phase II Study of High-Dose Paclitaxel With or Without Amifostine in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsCancer, 1997
- Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintainedEuropean Journal Of Cancer, 1997
- Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.Journal of Clinical Oncology, 1997
- Evaluation of long-term toxicity after chemotherapy for testicular cancer.Journal of Clinical Oncology, 1996
- Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.Journal of Clinical Oncology, 1996
- Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II studyBritish Journal of Cancer, 1995